Dynogen Presents Results Of Its Positive Phase 2a IBS-c Study With DDP733
Dynogen Pharmaceuticals, Inc. announced the presentation of positive results from its Phase 2a clinical trial for DDP733 (pumosetrag) as a treatment for irritable bowel syndrome with constipation (IBS-c) at the Digestive Disease Week 2008 (DDW) scientific meeting.
More: continued here
Filed under: Irritable-Bowel Syndrome on May 22nd, 2008